外陰がん(Vulvar Cancer):治療薬開発パイプライン動向(2016年下半期版)

調査会社Global Markets Direct社が発行したリサーチレポート(データ管理コード:DATA70209220)
◆英語タイトル:Vulvar Cancer - Pipeline Review, H2 2016
◆発行会社/調査会社:Global Markets Direct
◆商品コード:DATA70209220
◆発行日:2016年11月30日
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆ページ数:76
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥216,000見積依頼/購入/質問フォーム
Site LicenseUSD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
Enterprisewide (Global Site License)USD6,000 ⇒換算¥648,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[外陰がん(Vulvar Cancer):治療薬開発パイプライン動向(2016年下半期版)]についてメールでお問い合わせはこちら
当調査レポートでは、世界における外陰がん(Vulvar Cancer)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。
・イントロダクション
・外陰がん(Vulvar Cancer)の概要
・外陰がん(Vulvar Cancer)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・外陰がん(Vulvar Cancer)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・企業別、開発中の製品
・大学/研究機関別、研究中の製品
・外陰がん(Vulvar Cancer)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・外陰がん(Vulvar Cancer)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
*** レポート概要(サマリー)***

Vulvar Cancer – Pipeline Review, H2 2016

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Vulvar Cancer – Pipeline Review, H2 2016, provides an overview of the Vulvar Cancer (Oncology) pipeline landscape.

Vulvar cancer is a rare type of cancer. It forms in a woman’s external genitals, called the vulva. The cancer usually develops slowly over several years. First, precancerous cells grow on vulvar skin. This is called vulvar intraepithelial neoplasia (VIN), or dysplasia. Not all VIN cases turn into cancer, but it is best to treat it early.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Vulvar Cancer – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Vulvar Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vulvar Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Vulvar Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II stages are 5 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.Vulvar Cancer.

Vulvar Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Vulvar Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Vulvar Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Vulvar Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Vulvar Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Vulvar Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Vulvar Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Vulvar Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

*** レポート目次(コンテンツ)***

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Vulvar Cancer Overview 6
Therapeutics Development 7
Pipeline Products for Vulvar Cancer – Overview 7
Pipeline Products for Vulvar Cancer – Comparative Analysis 8
Vulvar Cancer – Therapeutics under Development by Companies 9
Vulvar Cancer – Therapeutics under Investigation by Universities/Institutes 10
Vulvar Cancer – Pipeline Products Glance 11
Clinical Stage Products 11
Vulvar Cancer – Products under Development by Companies 12
Vulvar Cancer – Products under Investigation by Universities/Institutes 13
Vulvar Cancer – Companies Involved in Therapeutics Development 14
Cutanea Life Sciences Inc 14
ISA Pharmaceuticals BV 15
Ono Pharmaceutical Co Ltd 16
Oryx GmbH & Co KG 17
PDS Biotechnology Corp 18
Vulvar Cancer – Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
Cellular Immunotherapy for HPV Associated Cancers – Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
ISA-101 – Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
nivolumab – Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
omiganan pentahydrochloride – Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
PDS-0101 – Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
Vicoryx – Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
Vulvar Cancer – Dormant Projects 72
Vulvar Cancer – Product Development Milestones 73
Featured News & Press Releases 73
Oct 05, 2011: FDA Grants ISA Pharmaceuticals Orphan Drug Designation For Treatment Of Vulvar Intraepithelial Neoplasia With ISA-HPV-SLP 73
Mar 07, 2011: ISA Pharma Receives €2.7m From Dutch Government To Further Clinical Development Of HPV-SLP Vaccine 73
Jun 02, 2010: Bachem To Supply ISA Pharmaceuticals With Finished Dosage Forms Immunotherapeutic HPV-SLP For Phase III Clinical Trials 73
Jun 02, 2010: Bachem To Supply ISA Pharmaceuticals With Finished Dosage Forms Immunotherapeutic HPV-SLP For Phase III Clinical Trials 74
Appendix 75
Methodology 75
Coverage 75
Secondary Research 75
Primary Research 75
Expert Panel Validation 75
Contact Us 75
Disclaimer 76

List of Tables
Number of Products under Development for Vulvar Cancer, H2 2016 7
Number of Products under Development for Vulvar Cancer - Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Number of Products under Investigation by Universities/Institutes, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Products under Development by Companies, H2 2016 12
Products under Investigation by Universities/Institutes, H2 2016 13
Vulvar Cancer - Pipeline by Cutanea Life Sciences Inc, H2 2016 14
Vulvar Cancer - Pipeline by ISA Pharmaceuticals BV, H2 2016 15
Vulvar Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 16
Vulvar Cancer - Pipeline by Oryx GmbH & Co KG, H2 2016 17
Vulvar Cancer - Pipeline by PDS Biotechnology Corp, H2 2016 18
Assessment by Monotherapy Products, H2 2016 19
Number of Products by Stage and Target, H2 2016 21
Number of Products by Stage and Mechanism of Action, H2 2016 23
Number of Products by Stage and Route of Administration, H2 2016 25
Number of Products by Stage and Molecule Type, H2 2016 27
Vulvar Cancer - Dormant Projects, H2 2016 72

List of Figures
Number of Products under Development for Vulvar Cancer, H2 2016 7
Number of Products under Development for Vulvar Cancer - Comparative Analysis, H2 2016 8
Comparative Analysis by Clinical Stage Development, H2 2016 11
Assessment by Monotherapy Products, H2 2016 19
Number of Products by Targets, H2 2016 20
Number of Products by Stage and Targets, H2 2016 20
Number of Products by Mechanism of Actions, H2 2016 22
Number of Products by Stage and Mechanism of Actions, H2 2016 22
Number of Products by Routes of Administration, H2 2016 24
Number of Products by Stage and Routes of Administration, H2 2016 24
Number of Products by Molecule Types, H2 2016 26
Number of Products by Stage and Molecule Types, H2 2016 26

*** レポートのキーワード ***

外陰がん(Vulvar Cancer)

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
  • 家電産業における産業用ロボットの世界市場2018-2022
    About Industrial Robots Industrial robots comprise of high-tech hardware components such as smart sensors, controllers, motor, and software. These components increase their associative cost considerably. Industrial players do not install a single robot, rather they automate the factory with robots t …
  • 世界の電子皮膚パッチ市場予測:2021-2028
    KEY FINDINGS The global electronic skin patches market is evaluated to project a CAGR of 16.89%, during the forecast period of 2021 to 2028. The market growth is attributed to factors, such as, the surging demand for periodic health monitoring, the growing incidence of lifestyle-associated and chron …
  • セラミックテープの世界市場:販売動向2017
    Notes:Sales, means the sales volume of Ceramic Tape Revenue, means the sales value of Ceramic Tape This report studies sales (consumption) of Ceramic Tape in Global market, especially in United States, China, Europe and Japan, focuses on top players in these regions/countries, with sales, price, rev …
  • 流体動力シリンダーの世界市場2021-2026:成長・動向・新型コロナの影響・市場予測
    The Fluid Power Cylinder Market is expected to register a CAGR greater than 4.5% during the forecast period (2021 - 2026). The advent of jet engines for military and passenger aircrafts had spurred the use of centrifugal and axial-flow compressors. Further, the growth of automatic machinery, labor-s …
  • C13-C16イソパラフィンの世界市場2021
    The Global C13-C16 Isoparaffin (CAS 68551-20-2) Industry 2021 Market Research Report is a professional and in-depth study on the current state of the C13-C16 Isoparaffin industry. Firstly, the report provides a basic overview of the industry including definitions, classifications, applications and i …
  • エチレンの世界市場動向・予測
    The present report is an essential resource for a one looking for detailed information on the world ethylene market. The report covers data on global, regional and national markets including present and future trends for supply and demand, prices, and downstream industries. In addition to the analyt …
  • 世界の電子機器受託製造サービス(EMS)市場2021年-2025年
    Electronics Manufacturing Services Market 2021-2025 Technavio has been monitoring the electronics manufacturing services market and it is poised to grow by $ 121.80 bn during 2021-2025 progressing at a CAGR of 5% during the forecast period. Our report on electronics manufacturing services market pro …
  • 世界の消費者向け文房具小売市場2020-2024
    Global Consumer Stationery Retailing Market 2020-2024 Technavio has been monitoring the consumer stationery retailing market and it is poised to grow by $ 6.35 bn during 2020-2024 progressing at a CAGR of 2% during the forecast period. Our reports on consumer stationery retailing market provides a h …
  • テミビンホスの世界市場2021
    The Global Temivinphos (CAS 35996-61-3) Industry 2021 Market Research Report is a professional and in-depth study on the current state of the Temivinphos industry. Firstly, the report provides a basic overview of the industry including definitions, classifications, applications and industry chain st …
  • 自動貯水システムの世界市場 2019年-2023年
    In the context of China-US trade war and global economic volatility and uncertainty, it will have a big influence on this market. Automatic Water Storage System Report by Material, Application, and Geography – Global Forecast to 2023 is a professional and comprehensive research report on the world’s …
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(DATA70209220 )"外陰がん(Vulvar Cancer):治療薬開発パイプライン動向(2016年下半期版)" (英文:Vulvar Cancer - Pipeline Review, H2 2016)はGlobal Markets Direct社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。